1. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
   M. Lazenby et al, 2015, Leukemia Research CrossRef
2. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells
   Namrata Khurana et al, 2016 CrossRef
3. Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells
   Kazuaki Kita et al, 2017, Cancer Sci CrossRef
4. Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload
   Jose A. Suárez del Pino et al, 2017, Pharm Res CrossRef
5. BIIB021: A novel inhibitor to heat shock protein 90–addicted oncology
   Liang Yan et al, 2017, Tumour Biol. CrossRef
6. ALDH1A3 correlates with luminal phenotype in prostate cancer
   Shangqian Wang et al, 2017, Tumour Biol. CrossRef
7. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer
   Namrata Khurana et al, 2017 CrossRef
8. The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
   Roberto Gomez-Casal et al, 2015, Cancers CrossRef
9. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90
   Alex Henke et al, 2016, Cancers CrossRef
10. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
    Keith H. Jansson et al, 2018, Sci Rep CrossRef
11. Targeting heat shock proteins in metastatic castration-resistant prostate cancer
    Arun A. Azad et al, 2015, Nat Rev Urol CrossRef
12. null
    David A. Proia et al, 2015 CrossRef
13. The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90β and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth
    Daniela Brünnert et al, 2019, J Cell Biochem CrossRef
14. Hsp90: Still a viable target in prostate cancer
    Margaret M. Centenera et al, 2013, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
15. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
    Julie C. Friedland et al, 2014, Invest New Drugs CrossRef
16. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Ayesha A Shafi et al, 2013, Pharmacol Ther CrossRef
17. Advances in Androgen Receptor Targeted Therapy for Prostate Cancer
    Alia Ahmed et al, 2014, J. Cell. Physiol. CrossRef
18. Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition
    Guanxiong Ding et al, 2013, PLoS ONE CrossRef
19. Androgen receptor signaling in prostate cancer
    Zoran Culig et al, 2014, Cancer Metastasis Rev CrossRef
20. Heat Shock Protein 90 is Associated with Hyperplasia and Neoplastic Transformation of Canine Prostatic Epithelial Cells
    C. Palmieri et al, 2014, Journal of Comparative Pathology CrossRef
21. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
    Suqin He et al, 2014, Invest New Drugs CrossRef
22. Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
    Mary Nakazawa et al, 2014, HORM CANC CrossRef
23. Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer
    Su Liang et al, 2016, Pharmaceutical Development and Technology CrossRef
24. The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer
    null Hoter et al, 2019, Cancers CrossRef
25. The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus
    Yuan Liu et al, 2015, PLoS ONE CrossRef
26. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms
    Margaret M Centenera et al, 2015 CrossRef
27. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
    Christopher Foley et al, 2016, HORM CANC CrossRef
28. Androgen receptor variation affects prostate cancer progression and drug resistance
    Edel McCrea et al, 2016, Pharmacological Research CrossRef
29. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52
    Jugal Bharat Joshi et al, 2017, Mol Oncol CrossRef
30. null
    Asmaa Aboelnour et al, 2019 CrossRef
31. Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells
    Thanakorn Pungsrinont et al, 2020, Cell Biosci CrossRef
32. Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
    Christos E. Kyriakopoulos et al, 2020, JCO CrossRef
33. Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation
    Yifan Wang et al, 2016, Clin Cancer Res CrossRef
34. A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer
    Mark A. Socinski et al, 2013, Clin Cancer Res CrossRef
35. Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
    David A. Proia et al, 2014, Clin Cancer Res CrossRef
36. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer
    Michael A. Moses et al, 2018, Cancer Res CrossRef
37. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
    Rita Lombardi et al, 2021, Mol Oncol CrossRef
38. Advances in the role of heat shock protein 90 in prostate cancer
    Zheng Fu et al, 2022, Andrologia CrossRef
39. Resistance to prostate cancer treatments
    Werner Krause, 2022, IUBMB Life CrossRef
40. The endoplasmic reticulum stress response in prostate cancer
    Claire M. de la Calle et al, 2022, Nat Rev Urol CrossRef
41. The evolution and polymorphism of mono-amino acid repeats in androgen receptor and their regulatory role in health and disease
    Attila Meszaros et al, 2022, Front. Med. CrossRef
42. null
    Weiwen Ying, 2013 CrossRef
43. null
    Emin Avsar, 2013 CrossRef
44. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
    Mahmoud E. Youssef et al, 2023, IJMS CrossRef
45. Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer
    Siqi Zhang et al, 2023, J. Med. Chem. CrossRef
46. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer
    Shohei Yoshida et al, 2024, Molecular Oncology CrossRef